Market Research Logo

Asia-pacific Dna Vaccines Market Forecast 2017-2025

Asia-pacific Dna Vaccines Market Forecast 2017-2025

KEY FINDINGS
The Asia-Pacific DNA vaccine market was calculated to be worth $154 million in 2016 and is predicted to generate a revenue of $4874 million by 2025, growing at a CAGR of 45.85%.

MARKET INSIGHTS
The Asia-Pacific market is predicted to witness the highest growth over the forecast period due to factors like increasing government backing, growing interest in third generation vaccine innovations, and growing number of medical service organizations in the region. The APAC market is segmented on the basis of technology, types, and applications. The major aspects threatening the market expansion for this region include the lengthy regulatory process and the poor patent protection methodologies.

COMPETITIVE INSIGHTS
Some of the leading companies in the market include Zoetis Inc, Merck & Co, Glaxosmithkline Inc, Sanofi, Astellas Pharma Inc, Novartis Ag, Xenetic Biosciences Inc, Madison Vaccines Incorporated (MVI), Dendreon Corporation, and Eli Lilly And Company.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
4. Market Determinants
4.1. Drivers
4.1.1. Dna Vaccines Showing Great Promise For Checking Rising Prevalence Of Disease
4.1.2. Third Generation Vaccination Is Witnessing A Surge In Investment
4.1.3. Increasing Adoption Of Dna Vaccines For Animal Healthcare
4.2. Restraints
4.2.1. Lengthy Regulatory Process
4.2.2. Poor Patent Protection In Some Countries
4.3. Opportunities
4.3.1. Transforming Healthcare Landscape
4.3.2. New Developments In Biotechnology And Nanotechnology
4.3.3. Stable Vaccines Make It Attractive To Store And Transport
4.4. Challenges
4.4.1. Vaccines For Human Usage Still Under Clinic Trail Phase
5. Market Segmentation
5.1. Market By Type 2017-2025
5.1.1. Animal Dna Vaccine
5.1.2. Human Dna Vaccine
5.2. Market By Application 2017-2025
5.2.1. Human Disease
5.2.2. Veterinary Disease
5.3. Market By Technology 2017-2025
5.3.1. Plasmid Dna Vaccines
5.3.2. Plasmid Dna Delivery
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Threats Of Substitute Product
6.1.3. Bargaining Power Of Buyer
6.1.4. Bargaining Power Of Supplier
6.1.5. Intensity Of Competitive Rivalry
6.2. Key Buying Criteria
6.2.1. Efficacy
6.2.2. Cost-effectiveness
6.2.3. Stability
6.3. Key Market Players
6.3.1. Vical Incorporated
6.3.2. Sanofi
6.3.3. Merck And Corp
6.3.4. Gsk
6.4. Opportunity Matrix
6.5. Value Chain Analysis
6.5.1. R&D
6.5.2. Manufacturing
6.5.3. Raw Materials
6.5.4. Marketing, Distribution & End User
6.6. Legal, Policy And Regulatory Framework
7. Geographical Analysis
7.1. Asia Pacific
7.1.1. India
7.1.2. China
7.1.3. Japan
7.1.4. Australia
7.1.5. Rest Of Asia Pacific
8. Competitive Landscape
8.1. Strategic Initiatives
8.1.1. Acquisition
8.1.2. Partnership
8.1.3. Collaboration
8.1.4. Innovation
8.1.5. Disinvestment
8.1.6. Expansion
9. Company Profile
9.1. Market Share
9.2. Astellas Pharma Inc.
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Scot Analysis
9.2.4. Strategic Initiative
9.3. Dendreon Corporation (Acquired By Sanpower Group)
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Scot Analysis
9.3.4. Strategic Initiative
9.4. Eli Lilly And Company
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Scot Analysis
9.4.4. Strategic Initiative
9.5. Eurogentec S.A
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Scot Analysis
9.5.4. Strategic Initiative
9.6. Glaxosmithkline Inc.
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Scot Analysis
9.6.4. Strategic Initiatives
9.7. Inovio Pharmaceuticals, Inc.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Scot Analysis
9.7.4. Strategic Initiative
9.8. Madison Vaccines Incorporated (Mvi)
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Scot Analysis
9.9. Merial Limited (Acquired By Boehringer Ingelheim)
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.9.4. Strategic Initiative
9.10. Merck & Co.
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Scot Analysis
9.10.4. Strategic Initiative
9.11. Novartis Ag
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Scot Analysis
9.11.4. Strategic Initiative
9.12. Sanofi
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Scot Analysis
9.12.4. Strategic Initiative
9.13. Vgxi
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Scot Analysis
9.13.4. Strategic Initiatives
9.14. Vical Incorporated
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Scot Analysis
9.14.4. Strategic Initiative
9.15. Xenetic Biosciences Inc.
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Scot Analysis
9.15.4. Strategic Initiative
9.16. Zoetis Inc
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Scot Analysis
9.16.4. Strategic Initiative  
Table List
Table 1 Asia Pacific Dna Vaccine Market 2017-2025 ($ Million)
Table 2 Interventions And Phase Of Certain Disease/Conditions
Table 3 Approaches Being Tested To Enhance The Low Immunogenicity
Table 4 Clinical Trials For Humans Involving Dna Vaccines
Table 5 Temperature Requirements In Preservation For Various Vaccines
Table 6 Asia Pacific Dna Vaccine Market By Type 2017-2025 ($ Million)
Table 7 Asia Pacific Animal Dna Vaccine Market 2017-2025($million)
Table 8 Asia Pacific Human Dna Vaccine Market 2017-2025
Table 9 Asia Pacific Dna Vaccine Market By Application 2017-2025 ($ Million)
Table 10 Asia Pacific Human Diseases Application Market 2017-2025 ($million)
Table 11 Asia Pacific Veterinary Application Markets 2017-2025
Table 12 Asia Pacific Dna Vaccine Market By Technology 2017-2025 ($ Million)
Table 13 Asia Pacific Plasmid Dna Vaccines Technology Market 2017-2025
Table 14 Asia Pacific Plasmid Dna Delivery Technology Markets 2017-2025
Table 15 Regulations To Be Followed Before Commercialization
Figure List
Figure 1 Asia Pacific Dna Vaccine Market 2017-2025 ($ Million)
Figure 2 Asia Pacific Dna Vaccine Market In Veterinary Diseases 2017-2025 ($ Million)
Figure 3 Share Of Trials By Vaccine Target In 2016
Figure 4 Segment Of Clinical Trials Of Dna Vaccine By Cancer Markers In 2016
Figure 5 Clinical Trials Of Gene Therapy
Figure 6 Asia Pacific Dna Vaccine Market Share By Type 2016 & 2025 (%)
Figure 7 Asia Pacific Dna Vaccines Market In Animal Dna Vaccines 2017-2025 ($ Million)
Figure 8 Asia Pacific Dna Vaccine Market In Human Dna Vaccines 2017-2025($ Million)
Figure 9 Asia Pacific Dna Vaccine Market Share By Application 2016 & 2025 (%)
Figure 10 Asia Pacific Dna Vaccines Market In Human Diseases 2017-2025 ($ Million)
Figure 11 Asia Pacific Dna Vaccines Market In Veterinary Application 2017-2025 ($ Million)
Figure 12 Asia Pacific Dna Vaccines Market In Plasmid Dna Vaccines Technology 2017-2025 ($ Million)
Figure 13 Asia Pacific Dna Vaccines Market In Plasmid Dna Delivery Technology 2017-2025 ($ Million)
Figure 14 Value Chain Analysis For Dna Vaccine Industry
Figure 15 India Dna Vaccine Market 2017-2025 ($ Million)
Figure 16 China Dna Vaccine Market 2017-2025 ($ Million)
Figure 17 Japan Dna Vaccine Market 2017-2025 ($ Million)
Figure 18 Australia Dna Vaccine Market 2017-2025 ($ Million)
Figure 19 Rest Of Asia Pacific Dna Vaccine Market 2017-2025 ($ Million)
Figure 20 Market Shares Of Top Five Companies For Dna Vaccines Market In 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report